Clinica Chimica Acta 2012-12-24

LC–MS/MS analysis of plasma lyso-Gb3 in Fabry disease

Michel Boutin, René Gagnon, Pamela Lavoie, Christiane Auray-Blais

文献索引：Clin. Chim. Acta 414 , 273-80, (2012)

全文：HTML全文

摘要

Background Fabry disease is a complex, multisystemic and clinically heterogeneous disease, with elevated excretion of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3) accumulating in biological fluids caused by deficiency of the enzyme, lysosomal α-galactosidase A. Our aims were to propose a tandem mass spectrometry fragmentation mechanism for lyso-Gb3, to develop and validate a simple, and robust methodology for the measurement of plasma lyso-Gb3 using LC–MS/MS in large Fabry cohorts and in controls. Response to treatment was also evaluated.

相关化合物

  • α-D-Gal-(1→4)-β-D...

相关文献：

A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers.

2013-01-01

[Curr. Med. Chem. 20(2) , 280-8, (2013)]

In vivo tumor targeting using a novel intestinal pathogen-based delivery approach.

2006-07-15

[Cancer Res. 66(14) , 7230-6, (2006)]

Plasma globotriaosylsphingosine as a biomarker of Fabry disease.

2010-07-01

[Mol. Genet. Metab. 100(3) , 257-61, (2010)]

Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry.

2012-02-01

[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 883-884 , 128-35, (2012)]

Induction of cytokines by toxins that have an identical RNA N-glycosidase activity: Shiga toxin, ricin, and modeccin.

2004-03-17

[Biochim. Biophys. Acta 1671(1-3) , 44-50, (2004)]

更多文献...